Structure Therapeutics appoints Matthew Lang, J.D. as Chief Operating Officer and General Counsel. SAN FRANCISCO, April 14, 2026 (GLOBE NEWSWIRE) - Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obesity, today announced the appointment of Matthew Lang, J.D. as Chief Operating Officer and General Counsel. Mr. Lang joins Structure Therapeutics with more than fifteen years of executive leadership experience across global biopharmaceutical organizations, with deep expertise spanning legal, corporate strategy, compliance, risk management, and business development. "Matt is a proven leader with a strong track record of guiding organizations through growth and transformation," said Raymond Stevens, Ph.D., CEO of Structure Therapeutics. "His experience across global operations, strategic transactions, and commercialization will be critical as we move aleniglipron into Phase 3 and continue to build a world-class leadership team." Mr. Lang most recently served as Chief Legal Officer and Secretary at Metsera, Inc., helping to guide the company through its up to $10 billion acquisition by Pfizer. Prior to Metsera, Mr. Lang served as Chief Business and Legal Officer at Lyell Immunopharma, Inc., and held several executive officer positions at Myovant Sciences, where he helped lead the company through Phase 3 clinical development, global approval and commercialization of Myfembree(R) and Orgovyx(R). Mr. Lang also served as the Managing Director and General Manager of Myovant's European operations in Basel Switzerland where he was responsible for all aspects of Myovant's ex-US business operations. Earlier in his career Mr. Lang held roles of increasing seniority at Gilead Sciences, Inc., and was an attorney at Dechert, LLP. He received his B.A. in Classical Studies from Queen's University at Kingston, Canada and his J.D. from the University of Pennsylvania Law School. "I am excited to join Structure Therapeutics at this important stage as we move into Phase 3 development with one of the most promising late-stage assets in the competitive obesity landscape," said Mr. Lang. "The Company's mission and differentiated portfolio represent a compelling opportunity to deliver a complete pipeline of meaningful therapies to patients. I look forward to working with the team to further strengthen the Company's operational foundation, execute on strategic priorities, and drive long-term value." About Structure Therapeutics Structure Therapeutics is a science-driven clinical-stage biopharmaceutical company focused on discovering and developing innovative oral small molecule treatments for chronic metabolic conditions with significant unmet medical needs. Utilizing its next generation structure-based drug discovery platform, the Company has established a robust GPCR-targeted pipeline, featuring multiple wholly-owned proprietary clinical-stage oral small molecule compounds designed to surpass the scalability limitations of traditional biologic and peptide therapies and be accessible to more people living with obesity around the world. For additional information, please visit www.structuretx.com. Forward Looking Statements This press release contains "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact are statements that could be deemed forward-looking statements, including, without limitation, statements concerning: the Company's future plans and prospects; and any expectations regarding the potential benefits, tolerability and safety profile, accessibility, scalability, combinability, capability, efficacy, convenience, expected effects and future application of aleniglipron and any other of the Company's investigational compounds. In addition, when or if used in this press release, the words and phrases "anticipated," "believe," "expect," "may," "on track," "plan," "potential," "suggests," "to be," "to begin," "will," and similar expressions and their variants, as they relate to the Company may identify forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Although the Company believes the expectations reflected in such forward-looking statements are reasonable, the Company can give no assurance that such expectations will prove to be correct. Readers are cautioned that actual results, levels of activity, safety, performance or events and circumstances could differ materially from those expressed or implied in the Company's forward-looking statements due to a variety of risks and uncertainties, which include, without limitation: risks and uncertainties related to potential delays in the commencement, enrollment and completion of the Company's planned clinical studies; the Company's ability to advance aleniglipron, ACCG-2671, ACCG-3535, ANPA-0073, LTSE-2578, and its other therapeutic candidates, obtain regulatory approval of, and ultimately commercialize the Company's therapeutic candidates; competitive products or approaches limiting the commercial value of the Company's product candidates; the Company's ability to fund development activities and achieve development goals; and other risks and uncertainties described in the Company's filings with the Securities and Exchange Commission (SEC), including the Company's latest Annual Report on Form 10-K and future reports the Company may file with the SEC from time to time. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management's assumptions and estimates as of such date. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law. Investors: Corey Davis, Ph.D. LifeSci Advisors, LLC 212-915-2577 [email protected]

Lyell Immunopharma stock: what investors should know before buying now. 09.04.2026 - 13:05:37 | ad-hoc-news.de You're eyeing biotech plays with big potential in immunotherapy - Lyell Immunopharma could fit your portfolio, but understanding its tech and risks is key for smart decisions across U.S., Europe, or global markets. This report breaks down the business, catalysts, and what analysts say to help you decide. ISIN: US55083R1041 Considering a position in Lyell Immunopharma stock? This clinical-stage biotech focuses on transforming solid tumor treatments through next-generation immunotherapies, making it a name worth watching if you're building exposure to innovative cancer therapies. The company trades on Nasdaq under ticker LYEL, with shares denominated in USD. As a U.S.-listed entity headquartered in South San Francisco, California, Lyell appeals to investors worldwide seeking high-growth opportunities in biotechnology. Its platform targets T-cell exhaustion and other barriers in solid tumors, positioning it uniquely in a competitive field. As of: 09.04.2026 By Elena Vargas, Senior Biotech Equity Analyst: Lyell Immunopharma stands at the intersection of cutting-edge cell therapy and oncology, offering potential breakthroughs for investors patient with clinical timelines. Understanding Lyell's core business model. Official source Find the latest information on Lyell Immunopharma directly on the company's official website. Lyell Immunopharma develops programmable T-cell therapies designed to overcome the challenges of treating solid tumors. Unlike many biotechs chasing broad-spectrum drugs, you get a company laser-focused on reprogramming exhausted T cells - the immune system's frontline soldiers that often fail in cancer battles. Its lead candidates include LYL797, a checkpoint inhibitor targeting the Protein Tyrosine Phosphatase Receptor Type N2 (PTPN2/N1), and others like LYL719 for regulatory T cells. These therapies aim to enhance T-cell persistence and function directly in the tumor microenvironment. For you as an investor, this means betting on platform tech that could apply across multiple cancer types, from lung to melanoma. The business model relies on advancing its pipeline through clinical trials while forming strategic partnerships. Lyell has collaborations with big names in pharma, providing non-dilutive funding and validation. This setup reduces some cash burn risks typical in early-stage biotech, but you'll still need to track trial readouts closely. Revenue remains preclinical or early clinical-stage typical: minimal for now, with value hinging on milestones and potential approvals years out. If you're in it for the long haul, Lyell's multi-product platform offers scalability that single-asset biotechs lack. Key products and pipeline progress. Sentiment and reactions At the heart of Lyell's value proposition is its pipeline, anchored by several clinical-stage assets. LYL797, an allogenic therapy, is in Phase 1 trials for advanced solid tumors, showing early promise in reinvigorating T cells without the toxicity of broader checkpoint inhibitors. Complementing this, Lyell's rasG12C program targets a specific mutation common in lung and colorectal cancers, combining small molecules with its immunotherapy platform. You should note how these programs address unmet needs: solid tumors resist CAR-T success seen in blood cancers, and Lyell's approach could bridge that gap. Preclinical efforts include next-gen CAR-T and TIL (tumor-infiltrating lymphocyte) enhancements. Progress here matters because positive data could trigger partnerships or buyouts - common exits for platform biotechs. Track upcoming trial updates; they're your signals for entry or expansion points. For global investors, the universal nature of cancer makes Lyell's work relevant everywhere. European and U.S. regulatory paths align closely for oncology, easing cross-border appeal. Competitive landscape and industry drivers. In the cutthroat world of immuno-oncology, Lyell competes with giants like Bristol Myers Squibb, Merck, and pure-plays such as CRISPR Therapeutics or Allogene. What sets Lyell apart? Its focus on T-cell reprogramming via gene edits and protein targets, rather than just PD-1 blockers. Industry tailwinds favor Lyell: global cancer incidence rises, with solid tumors comprising 90% of cases. Advances in sequencing personalize treatments, amplifying platform plays like Lyell's. Macro drivers include aging populations in the U.S. and Europe, plus increasing healthcare spend on precision medicine. However, competition intensifies. If a rival hits a Phase 2 homerun first, Lyell's stock could lag. You need to weigh Lyell's differentiated mechanisms against broader sector momentum - biotech indices have rebounded, but volatility persists. Strategic alliances bolster Lyell's edge. Past deals with Takeda and others provide expertise and cash, helping navigate FDA/EMA hurdles that trip up smaller players. Why Lyell matters to you as an investor now. Right now, Lyell Immunopharma stock draws attention because immunotherapy remains a hottest sector for growth-oriented portfolios. If you're allocating to biotech amid market rotations, Lyell's platform offers upside from multiple shots on goal, unlike single-asset risks. For U.S. investors, Nasdaq listing means easy access via standard brokers. Europeans can trade via international platforms, with ADR-like simplicity. Globally, the oncology focus transcends borders - cancer doesn't discriminate by geography. What should you buy now? It depends on your risk tolerance. The stock has underperformed broader benchmarks in recent years, trading at depressed levels that reflect clinical uncertainties. Yet, that same discount creates opportunity if data de-risks the pipeline. Diversify: pair with established pharma for balance. Relevance spikes with trial catalysts. Positive interim data could spark rallies, as seen in peers. Monitor cash runway - Lyell's balance sheet supports operations into late 2020s, buying time for proof-of-concept. Current analyst views on Lyell Immunopharma. Analysts from major banks and research houses maintain a cautious but intrigued stance on Lyell Immunopharma, reflecting the high-risk, high-reward nature of its clinical pipeline. Firms like JPMorgan, Cantor Fitzgerald, and HC Wainwright have issued coverage, often highlighting the potential of Lyell's T-cell engineering platforms while tempering enthusiasm with execution risks in solid tumor trials. Consensus leans toward Hold or Neutral ratings, with price targets suggesting modest upside from recent lows, predicated on positive data readouts. For instance, research notes emphasize LYL797's novel mechanism as a differentiator, but stress the need for Phase 1 expansion data to build conviction. You won't find aggressive Buy calls without more mature results, aligning with biotech norms. Reputable houses note Lyell's partnerships as a positive, providing validation without full dilution. Overall, the analyst picture advises watching for catalysts rather than chasing momentum - sound advice if you're building a thoughtful portfolio. Risks and key questions to watch. Further developments, reports, and context on the stock can be explored quickly through the linked overview pages. Biotech investing isn't for the faint-hearted, and Lyell carries classic risks: clinical trial failures top the list. A negative readout could tank the stock 50% overnight, as peers have shown. Competition from incumbents with deeper pockets adds pressure. Cash burn is another watchpoint. While runway extends, dilution via offerings remains possible if trials expand. Regulatory hurdles in oncology demand flawless execution - FDA holds or trial designs flaws could delay milestones. Open questions include partnership expansions and data durability. Will Lyell's edits sustain responses long-term? How does it stack in combo therapies? Track SEC filings, conferences like ASCO, and peer comparisons for clues. For you globally, currency fluctuations and regional approvals matter. U.S.-centric pipeline suits American investors, but EMA alignment aids Europeans. What to watch next and final thoughts. Keep eyes on upcoming clinical updates, particularly LYL797 dose escalations and rasG12C data. Earnings calls reveal cash position and partnership news - key for near-term moves. Broader biotech sentiment, influenced by rates and M&A, will sway LYEL too. Should you buy now? If convicted on immunotherapy's future and tolerant of volatility, a small position makes sense at current valuations. Otherwise, wait for de-risking catalysts. Always size appropriately - never more than 5% of your portfolio in one biotech. Integrate Lyell into a diversified strategy: balance with stable dividend payers or index funds. Your next steps: review IR site, scan trial registries, and follow sector news. Informed patience pays in biotech. Disclaimer: Not investment advice. Stocks are volatile financial instruments. Sollten anleger sofort verkaufen? Oder lohnt sich doch der Einstieg bei Lyell Immunopharma? Die neusten Lyell Immunopharma-Zahlen sprechen eine klare Sprache: Dringender Handlungsbedarf für Lyell Immunopharma-Aktionäre. Lohnt sich ein Einstieg oder sollten Sie lieber verkaufen? In der aktuellen Gratis-Analyse vom 14. April erfahren Sie was jetzt zu tun ist. Seit 2005 liefert der Börsenbrief trading-notes verlässliche Anlage-Empfehlungen - dreimal pro Woche, direkt ins Postfach. 100% kostenlos. 100% Expertenwissen. Trage einfach deine E-Mail Adresse ein und verpasse ab heute keine Top-Chance mehr. Jetzt abonnieren. Für. Immer. Kostenlos. en | US55083R1041 | LYELL IMMUNOPHARMA | boerse | 69111497 | bgmi

Lyell Immunopharma to present at 25th Annual Needham Virtual Healthcare Conference. The late-stage clinical company will showcase its pipeline of next-generation CAR T-cell therapies for cancer patients. Lyell Immunopharma's innovative CAR T-cell therapies aim to redefine the future of cancer treatment through advanced molecular engineering. South San Francisco Today Lyell Immunopharma, Inc., a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor (CAR) T-cell therapies for patients with cancer, today announced that members of its senior management team will present and participate in the 25th Annual Needham Virtual Healthcare Conference on Tuesday, April 14, 2026, at 11:00 am Eastern Time. Why it matters. Lyell's participation in this high-profile healthcare conference signals the company's continued progress in developing innovative CAR T-cell therapies, which have shown promise in treating various types of cancer. As a late-stage clinical company, Lyell's presentation will likely provide updates on its pipeline and clinical trial progress, which could be of interest to investors, industry analysts, and the broader medical community. The details. The live webcast of Lyell's presentation can be accessed through the Investors section of the company's website at www.lyell.com. A replay of the webcast will be available on the company's website following the presentation date. * The 25th Annual Needham Virtual Healthcare Conference will take place on Tuesday, April 14, 2026. * Lyell's presentation is scheduled for 11:00 am Eastern Time on April 14, 2026. The players. Lyell Immunopharma, Inc. A late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor (CAR) T-cell therapies for patients with cancer. The takeaway. Lyell's participation in the prestigious Needham Virtual Healthcare Conference underscores the company's progress in developing innovative CAR T-cell therapies, which have the potential to revolutionize cancer treatment through advanced molecular engineering.